Triple therapy aims to turn inoperable lung cancer into a surgical target
NCT ID NCT07561983
First seen May 13, 2026 · Last updated May 13, 2026
Summary
This study tests whether combining an immunotherapy drug (tislelizumab) with standard chemotherapy and a targeted artery treatment can shrink stage III lung cancer that cannot be removed by surgery. About 39 adults with newly diagnosed, unresectable non-small cell lung cancer will receive up to 4 cycles of the combination. If the tumor shrinks enough, they may become eligible for surgery, followed by more treatment. The main goal is to see how many patients remain cancer-free or without major events one year after starting treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TISLELIZUMAB are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Sichuan Cancer Hospital and Research Institute
Chengdu, Sichuan, 610041, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.